@incollection{,
	
					
					
					DBD66CD5B2139B6B43C2D15E37BDFE84
				,
	author={{Hayder Ch.Assad} and {Al Kufa university/college of pharmacy}},
	journal={{Global Journal of Medical Research}},
	journal={{GJMR}}2249-46180975-588810.34257/GJMR,
	address={Cambridge, United States},
	publisher={Global Journals Organisation}1452531
}

@book{b0,
	
	
		,
	title={{}}
		,
	author={{
			CDGibson
		} and {
			WKarmally
		} and {
			DJMcmahon
		}}
		
		
		
			,
	year={2012}
		
	

}

@book{b1,
	
	
		,
	title={{Randomized Pilot Study of Cabergoline, a Dopamine Receptor Agonist: Effects on Body Weight and Glucose Tolerance in Obese Adults Diabetes Obes Metab}}
		
			,
	year={2012}
			14
			
		
	

}

@incollection{b2,
	
	
		,
	title={{Effect of cabergoline on insulin sensitivity, inflammation, and carotid intima media thickness in patients with prolactinoma}}
		,
	author={{
			SSInancli
		} and {
			AUsluogullari
		} and {
			Ustu
		}}
		
		
	
	
		,
	journal={{Endocrine}}
		
			44
			
			,
	year={2013}
		
	

}

@incollection{b3,
	
	
		,
	title={{Current approaches for assessing insulin sensitivity and resistance in vivo: advantages, limitations, and appropriate usage}}
		,
	author={{
			RMuniyappa
		} and {
			SLee
		} and {
			HChen
		}}
		
		
	
	
		,
	journal={{Am J PhysiolEndocrinolMetab}}
		
			294
			
			,
	year={2008}
		
	

}

@book{b4,
	
	
		,
	title={{}}
		,
	author={{
			SMTaghavi
		} and {
			SSFatemi
		} and {
			HRokni
		}}
		
		
		
			,
	year={2012}
		
	

}

@incollection{b5,
	
	
		,
	title={{}}
	
	
		,
	journal={{Cabergoline Effect on Blood Sugar in Type}}
		
			2
		
	

}

@incollection{b6,
	
	
		,
	title={{Diabetic Patients with Oral Agent Failure}}
	
	
		,
	journal={{Med J Malaysia}}
		
			67
			4
			
		
	

}

@incollection{b7,
	
	
		,
	title={{Activation of dopamine D2 receptors simultaneously ameliorates various metabolic features of obese women}}
		,
	author={{
			PKok
		} and {
			FRoelfsema
		} and {
			MFrolich
		}}
		
		
	
	
		,
	journal={{AJP-Endocrinol Metab}}
		
			291
			,
	year={2006}
		
	

}

@incollection{b8,
	
	
		,
	title={{The Effects of Short Term Cabergoline Therapy on Disease Activity and Metabolic Parameters in Acromegaly}}
		,
	author={{
			NMerican
		} and {
			NSukor
		} and {
			ARazali
		}}
		
		
	
	
		,
	journal={{Journal of Endocrinology and Metabolism}}
		
			3
			1
			
			,
	year={2013}
		
	

}

@incollection{b9,
	
	
		,
	title={{Higher doses of cabergoline further improve metabolic parameters in patients with prolactinoma regardless of the degree of reduction in prolactin levels}}
		,
	author={{
			ACiresi
		} and {
			MAmato
		} and {
			VGuarnotta
		} and {
			Etal
		}}
		
		
		
	
	
		,
	journal={{Clinical Endocrinology}}
		
			79
			
			,
	year={2013}
		
	

}

@incollection{b10,
	
	
		,
	title={{Different Effects of Cabergoline and Bromocriptine on Metabolic and Cardiovascular Risk Factors in Patients with Elevated Prolactin Levels}}
		,
	author={{
			KrysiakRand Okopien
		} and {
			B
		}}
		
	
	
		,
	journal={{Basic ClinPharmacol Toxicol}}
		
			13
			8
			,
	year={2014}
		
	

}

@incollection{b11,
	
	
		,
	title={{Bromocriptine improves glycaemic control and serum lipid profile in obese Type 2 diabetic subjects: A new approach in the treatment of diabetes}}
		,
	author={{
			AHCincotta
		} and {
			AHMeier
		} and {
			MJCincotta
		}}
		
		
	
	
		,
	journal={{Expert OpinInvestig Drugs}}
		
			8
			
			,
	year={1999}
		
	

}

@incollection{b12,
	
	
		,
	title={{Efficacy and safety of add on therapy of bromocriptine with metformin in Indian patients with type 2 diabetes mellitus: A randomized open labeled phase IV clinical trial}}
		,
	author={{
			AGhosh
		} and {
			NSengupta
		} and {
			PSahana
		}}
		
		
	
	
		,
	journal={{Indian J Pharmacol}}
		
			46
			1
			
			,
	year={2014}
		
	

}

@book{b13,
	
	
		,
	title={{}}
		,
	author={{
			KGBina
		} and {
			AHCincotta
		}}
		
		
			,
	year={2000}
			,
	publisher={Dopaminergic}
		
	

}

@book{b14,
	
	
		,
	title={{The combination of cabergoline with metformin significantly improved glycemic control and insulin resistance better than metformin alone in patient with obesity and diabetes. Also the combination might have beneficial protective effect on B-cell of pancreas}}
		
	

}

@incollection{b15,
	
	
		,
	title={{Dopamine agonist treatment ameliorates hyperglycemia, hyperlipidemia, and the elevated basal insulin release from islets of ob/ob mice}}
		,
	author={{
			YLiang
		} and {
			MLubkin
		} and {
			HSheng
		}}
		
		
	
	
		,
	journal={{BiochimBiophysActa}}
		
			1405
			
			,
	year={1998}
		
	

}

@incollection{b16,
	
	
		,
	title={{Application of structural model of glucoseinsulin relations to assess beta-cell function and insulin sensitivity}}
		,
	author={{
			RCTurner
		} and {
			ASRudenski
		} and {
			DRMatthews
		}}
		
		
	
	
		,
	journal={{HormMetab Res}}
		
			24
			
			,
	year={1990}
		
	
	,
	note={Suppl}

}

@incollection{b17,
	
	
		,
	title={{Use and abuse of HOMA modeling}}
		,
	author={{
			TMWallace
		} and {
			JCLevy
		} and {
			DRMatthews
		}}
		
		
	
	
		,
	journal={{Diabetes Care}}
		
			27
			
			,
	year={2004}
		
	

}

@incollection{b18,
	
	
		,
	title={{Insulin sensitivity and lipid profile in prolactinoma patients before and after normalization of prolactin by dopamine agonist therapy}}
		,
	author={{
			KBerinder
		} and {
			TNystrom
		} and {
			CHoybye
		}}
		
		
	
	
		,
	journal={{Pituitary}}
		
			14
			3
			
			,
	year={2011}
		
	

}

@incollection{b19,
	
	
		,
	title={{BMI and Metabolic Profile in Patients with Prolactinoma before and After Treatment with Dopamine Agonists}}
		,
	author={{
			Dos SantosSilva
		} and {
			CMBarbosa
		} and {
			FRLima
		} and {
			GA
		}}
		
		
		
	
	
		,
	journal={{Obesity (Silver Spring)}}
		
			19
			
			,
	year={2011}
		
	

}

@incollection{b20,
	
	
		,
	title={{Weighted effects of bromocriptine treatment on glucose homeostasis during hyperglycemic versus euglycemic clamp conditions in insulin resistant hamsters: bromocriptine as a unique postprandial insulin Sensitizer}}
		,
	author={{
			MEzrokhi
		} and {
			LLuo
		} and {
			ACincotta
		}}
		
		
		S:2
	
	
		,
	journal={{J Diabetes Metab}}
		
			,
	year={2012}
		
	

}

@book{b21,
	
	
		,
	title={{}}
		,
	author={{
			FAnan
		} and {
			NTakahashi
		} and {
			MNakagawa
		}}
		
		
		
			,
	year={2005}
			54
			
		
	

}

@incollection{b22,
	
	
		,
	title={{Hyperinsulinemia: Cause or Consequence?}}
		,
	author={{
			BECorkey
		}}
	
	
		,
	journal={{Diabetes}}
		
			61
			1
			
			,
	year={2012}
		
	

}

@incollection{b23,
	
	
		,
	title={{A Mini review: Dopaminergic regulation of Insulin Secretion from the Pancreatic Islet}}
		,
	author={{
			AUstione
		} and {
			DPiston
		} and {
			PHarris
		}}
		
		
	
	
		,
	journal={{MolEndocrinol}}
		
			27
			8
			
			,
	year={2013}
		
	

}

@incollection{b24,
	
	
		,
	title={{Hyperglycemic clamp assessment of insulin secretory responses in normal subjects treated with olanzapine, risperidone, or placebo}}
		,
	author={{
			MOSowell
		} and {
			NMukhopadhyay
		} and {
			PCavazzoni
		}}
		
		
	
	
		,
	journal={{J ClinEndocrinolMetab}}
		
			87
			
			,
	year={2002}
		
	

}

@incollection{b25,
	
	
		,
	title={{Disruption of TEJ dopamine D2 receptor impairs insulin secretion and glucose intolerance}}
		,
	author={{
			IGarcia-Tornado
		} and {
			AMOrnstein
		} and {
			AChamson-Reig
		}}
		
		
	
	
		,
	journal={{Endocrinology}}
		
			151
			4
			
			,
	year={2010}
		
	

}

@incollection{b26,
	
	
		,
	title={{The Medical Treatment of Cushing's disease: Effectiveness of Chronic Treatment with the Dopamine Agonist Cabergoline in Patients Unsuccessfully Treated by Surgery}}
		,
	author={{
			RJBrown
		} and {
			KIRother
		} and {
			RPivonello
		} and {
			DeMartino
		} and {
			CCappabianca
		} and {
			P
		}}
		
		
		
		
		
	
	
		,
	journal={{J ClinEndocri nol Metab}}
		
			94
			1
			
			,
	year={2008. 2009}
		
	
	,
	note={Effects of beta-cell rest on beta-cell function: a review of clinical and 37}

}

@incollection{b27,
	
	
		,
	title={{Effect of chronic treatment with cabergoline and testosterone replacement on metabolic parameters in male patients with prolactinomas and hypogonadism}}
		,
	author={{
			MGaldiero
		} and {
			RAuriemma
		} and {
			PVitale
		}}
		
		
	
	
		,
	journal={{Endocrine Abstracts}}
		
			35
			P865
			,
	year={2014}
		
	

}

@incollection{b28,
	
	
		,
	title={{Utility of Homeostasis Model Assessment of B-Cell Function in Predicting Diabetes in 12,924 Healthy Koreans}}
		,
	author={{
			KCSung
		} and {
			GMReaven
		} and {
			KimSh
		}}
		
		
	
	
		,
	journal={{Diabetes Care}}
		
			33
			
			,
	year={2010}
		
	

}

@incollection{b29,
	
	
		,
	title={{Treatment of Type 2 Diabetes}}
	
	
		,
	journal={{Diabetes Care}}
		
			4
			34
		
	

}

@incollection{b30,
	
	
		,
	title={{Systemic Treatment With Sympatholytic Dopamine Agonists Improves Aberrant B-Cell Hyperplasia and GLUT2, Glucokinase, and Insulin Immunoreactive Levels in ob/ob Mice}}
		,
	author={{
			LTJetton
		} and {
			YLiang
		} and {
			AHCincotta
		}}
		
		
	
	
		,
	journal={{Pediatr Diabetes}}
		
			9
			3
			
			,
	year={2001}
		
	
	,
	note={Metabolism}

}

@incollection{b31,
	
	
		,
	title={{weight gain, and hyperglycemia in ob/ob mice}}
	
	
		,
	booktitle={{Bromocriptine: A Sympatholytic, D2-Dopamine Agonist for the}}
				
			,
	year={2011}
			71
			
		
	
	,
	note={DeFronzo RA}

}